Traws Pharma Reports Positive Phase 2 Ratutrelvir Data for COVID-19 and Expands Tivoxavir Marboxil Program for Influenza Prophylaxis

summarizeSummary

Traws Pharma announced the completion of enrollment and positive preliminary results for its Phase 2 COVID-19 study of ratutrelvir, while also revealing plans to develop tivoxavir marboxil as a prophylactic treatment for seasonal influenza.

check_boxKey Events

• Ratutrelvir Phase 2 Enrollment Complete

  Traws Pharma completed enrollment in its 90-patient, open-label Phase 2 study of ratutrelvir for mild-to-moderate COVID-19, including a arm for PAXLOVID-ineligible patients.

• Positive Preliminary Ratutrelvir Data

  Ongoing data analysis confirms ratutrelvir's differentiated profile with fewer adverse events, no viral rebounds to date, and faster time to sustained symptom resolution, including in PAXLOVID-ineligible patients.

• Tivoxavir Marboxil Expanded Indication

  The company is progressing tivoxavir marboxil (TXM) as a single monthly oral tablet for the prophylactic treatment of seasonal influenza, aiming for 28-day protection.

• Influenza Challenge Study Secured

  A human influenza prophylaxis challenge study time slot has been secured for June 2026 to advance TXM into registration studies.

auto_awesomeAnalysis

This filing provides significant positive updates on Traws Pharma's lead antiviral programs. The completion of enrollment and preliminary positive data for ratutrelvir in a Phase 2 COVID-19 study, particularly its differentiated profile and efficacy in PAXLOVID-ineligible patients, suggests a strong potential for this candidate. Concurrently, the expansion of tivoxavir marboxil into a prophylactic treatment for seasonal influenza, with a secured challenge study, opens a new and substantial market opportunity. For a clinical-stage biopharmaceutical company of this size, these advancements represent critical value inflection points, potentially de-risking its pipeline and expanding its addressable markets.